Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

News SummaryMost relevantAll newsSector newsTweets 

FDA Approves Breast-Cancer Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 06:05pm CET

--Drug packs Roche's Herceptin with chemotherapy agent

--Drug approved for use as a first-line, or initial treatment for advanced breast cancer

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent, and is meant to treat certain types of breast cancer that have spread to other parts of the body.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales of up to 5%.

Analysts said the approval was broader than expected. The drug can be marketed for initial treatment rather than just in patients who've tried other therapies, creating a "significantly larger patient population," said Simos Simeondis, an analyst at Cowen and Company.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

Agents like Kadcyla are called antibody-drug conjugates and they are the focus of intense interest in the pharmaceutical industry. Roche's Genentech unit has 25 such agents under development for different cancers, including eight in human studies.

The first such agent to gain FDA approval was Seattle Genetics Inc.'s (>> Seattle Genetics, Inc.) Adcetris, for Hodgkin's Lymphoma and another rare cancer. That company and ImmunoGen are each collaborating with big pharmaceutical firms including Bayer AG (BAYRY, BAYN.XE), Eli Lilly & Co. (>> Eli Lilly & Co.), GlaxoSmith Kline PLC (GSK, GSK.LN), Pfizer Inc. (>> Pfizer Inc.), Sanofi (>> Sanofi SA) to develop several types of new cancer drugs.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The study showed women receiving Kadcyla lived for an average of 31 months, which was about six months longer than women being treated with Xeloda and Tykerb.

However, like other cancer drugs Kadcyla has the potential to cause serious and life-threatening side effects from liver damage or heart problems. The drug can also cause severe birth defects so doctors need to make sure women of child-bearing age aren't pregnant before administering the product.

--Joseph Walker contributed to this story.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
08:09p ROCHE : Global Calcitriol (CAS 32222-06-3) Market- Roche, Sun Pharmaceutical Ind..
10:55a ROCHE : Westminster slips by Vulcans, 5-4
03/21 ROCHE : Discuss the Freeze Drying of High Concentration Biologics in the Run-up ..
03/21 LOXO ONCOLOGY : LOXO) Enters Collaboration Agreement with Ventana Medical System..
03/21 LOXO ONCOLOGY : Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collabo..
03/20 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – SVP Sold 6,231 shares of Sto..
03/20 ROCHE : Health and Human Services Department (HHS); Food and Drug Administration..
03/20 ROCHE : Does Mars Have Rings? Not Right Now, But Maybe One Day
03/18 ROCHE : Soap veteran Ken 'no diva'
03/17 ROCHE : New MagNA Pure 24 System by Roche offers labs improved flexibility and a..
More news
Sector news : Pharmaceuticals - NEC
09:14p MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:57p Court Victory Benefits Biogen And Its Tecfidera Rival Alike
10:18a BIOLINERX : Update And Preview Of The Company's Q4 And FY 2016 Financial Results..
09:41a SNIPPET ROUNDUP : Medica And Cell Medica Are In The Money, But Endo And Valeant ..
03/21 Binimetinib Withdrawal Reveals Array Of Issues
03/20 Corporate Venture Capital - Savior Of Medtech?
Financials ( CHF)
Sales 2017 53 114 M
EBIT 2017 18 375 M
Net income 2017 11 481 M
Debt 2017 8 488 M
Yield 2017 3,42%
P/E ratio 2017 18,52
P/E ratio 2018 16,90
EV / Sales 2017 4,21x
EV / Sales 2018 3,86x
Capitalization 214 969 M
More Financials
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 281  CHF
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.8.81%216 473
JOHNSON & JOHNSON10.45%344 961
PFIZER INC.5.45%203 963
NOVARTIS AG2.09%195 883
MERCK & CO., INC.8.56%175 469
SANOFI7.59%115 573
More Results